


We claim:

1. A compound of formula (I)



wherein

5 R^1 is hydrogen, chloro, methyl or methoxy,

R^2 is hydrogen or methoxy,

with the proviso that at least one of R^1 and R^2 is other than hydrogen,

G^1 represents chloro, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxycarbonyl, 5-membered aza-hetero-aryl, or the group -CH₂-OR³, -CH₂-NR⁴R⁵ or -C(=O)-NR⁴R⁶, wherein

10 R^3 is hydrogen, (C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl or phenyl,

(i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, (C₁-C₄)-alkoxy, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl, amino, aminocarbonyl, mono-(C₁-C₄)-alkylaminocarbonyl, di-(C₁-C₄)-alkylaminocarbonyl, (C₃-C₆)-cycloalkyl or up to three fluoro atoms,

15 and

(ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

and

(iii) said phenyl is optionally substituted with one or two substituents independently selected from the group consisting of fluoro, chloro, bromo, cyano, trifluoromethyl, trifluoromethoxy, (C₁-C₄)-alkyl and (C₁-C₄)-alkoxy,

5 R⁴ is hydrogen or (C₁-C₄)-alkyl,

R⁵ is hydrogen, (C₁-C₄)-alkyl, (C₁-C₄)-alkylcarbonyl, (C₃-C₆)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein

10 (i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, (C₁-C₄)-alkoxy, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl, aminocarbonyl, mono-(C₁-C₄)-alkylaminocarbonyl, di-(C₁-C₄)-alkylaminocarbonyl or (C₃-C₆)-cycloalkyl,

and

15 (ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

and

(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy, oxo and amino,

20 R⁶ is hydrogen, (C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein

25 (i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, (C₁-C₄)-alkoxy, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl, amino, aminocarbonyl, mono-(C₁-C₄)-alkylaminocarbonyl, di-(C₁-C₄)-alkylaminocarbonyl or (C₃-C₆)-cycloalkyl,

and

(ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

and

(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy, oxo and amino,

or

R⁴ and R⁵, or R⁴ and R⁶, respectively, are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 7-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N(R⁷) and O, and which may be substituted on ring carbon atoms with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, oxo, hydroxy, amino and aminocarbonyl, and wherein

R⁷ is hydrogen, (C₁-C₄)-alkyl, formyl or (C₁-C₄)-alkylcarbonyl,

and

G² represents chloro, cyano, (C₁-C₄)-alkyl, or the group -CR^{8A}R^{8B}-OH, -CH₂-NR⁹R¹⁰, -C(=O)-NR¹¹R¹² or -CH₂-OR¹⁵, wherein

R^{8A} and R^{8B} are independently selected from the group consisting of hydrogen, (C₁-C₄)-alkyl, cyclopropyl and cyclobutyl,

R⁹ is hydrogen or (C₁-C₄)-alkyl,

R¹⁰ is hydrogen, (C₁-C₄)-alkyl, (C₁-C₄)-alkylcarbonyl, (C₃-C₆)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein

(i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, amino, aminocarbonyl, mono-(C₁-C₄)-alkylaminocarbonyl or di-(C₁-C₄)-alkylaminocarbonyl,

and

(ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

and

(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy, oxo and amino,

5 R¹¹ is hydrogen or (C₁-C₄)-alkyl,

R¹² is hydrogen, (C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein

10 (i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, amino, aminocarbonyl, mono-(C₁-C₄)-alkylaminocarbonyl or di-(C₁-C₄)-alkylaminocarbonyl,

and

(ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

15 and

(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy, oxo and amino,

or

20 R⁹ and R¹⁰, or R¹¹ and R¹², respectively, are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 7-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N(R¹³), O, S and S(O)₂, and which may be substituted on ring carbon atoms with up to three substituents independently
25 selected from the group consisting of fluoro, (C₁-C₄)-alkyl, oxo, hydroxy, amino and aminocarbonyl, and wherein

R¹³ is hydrogen, (C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl, formyl or (C₁-C₄)-alkylcarbonyl,

and

R^{15} is (C₁-C₄)-alkyl,

with the proviso that G¹ is not chloro when G² is chloro or cyano,

or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

5 2. The compound of formula (I) according to Claim 1, wherein

R^1 is chloro, methyl or methoxy,

R^2 is hydrogen or methoxy,

10 G^1 represents chloro, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxycarbonyl or 5-membered aza-hetero-aryl selected from the group consisting of pyrazolyl, imidazolyl, oxazolyl, isoxazolyl and oxadiazolyl, or represents the group -CH₂-OR³ or -CH₂-NR⁴R⁵, wherein

R^3 is hydrogen, (C₁-C₄)-alkyl or (C₃-C₆)-cycloalkyl,

wherein said (C₁-C₄)-alkyl is optionally substituted with hydroxy, (C₁-C₄)-alkoxy, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl, amino, aminocarbonyl, (C₃-C₆)-cycloalkyl or up to three fluoro atoms,

15 R^4 is hydrogen or (C₁-C₄)-alkyl,

R^5 is hydrogen, (C₁-C₄)-alkyl, (C₁-C₄)-alkylcarbonyl, (C₃-C₆)-cycloalkyl or 5- or 6-membered heterocycloalkyl, wherein

(i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, hydroxycarbonyl or (C₃-C₆)-cycloalkyl,

20 and

(ii) said 5- or 6-membered heterocycloalkyl is optionally substituted with oxo,

or

25 R^4 and R^5 are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 6-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N(R⁷) and

O, and which may be substituted on a ring carbon atom with oxo or hydroxy, and wherein

R^7 is hydrogen or (C₁-C₄)-alkyl,

and

5 C^2 represents chloro, cyano, (C₁-C₄)-alkyl, or the group $-CR^{8A}R^{8B}-OH$, $-CH_2-NR^9R^{10}$, $-C(=O)-NR^{11}R^{12}$ or $-CH_2-OR^{15}$, wherein

R^{8A} and R^{8B} are independently selected from the group consisting of hydrogen, (C₁-C₄)-alkyl and cyclopropyl,

R^9 is hydrogen or methyl,

10 R^{10} is hydrogen, (C₁-C₄)-alkyl, (C₁-C₄)-alkylcarbonyl, (C₃-C₆)-cycloalkyl or 5- or 6-membered heterocycloalkyl, wherein

(i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy or amino-carbonyl,

and

15 (ii) said 5- or 6-membered heterocycloalkyl is optionally substituted with oxo,

R^{11} is hydrogen or methyl,

R^{12} is hydrogen, (C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl or 5- or 6-membered heterocycloalkyl, wherein

20 (i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy,

and

(ii) said 5- or 6-membered heterocycloalkyl is optionally substituted with oxo,

or

25 R^9 and R^{10} , or R^{11} and R^{12} , respectively, are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to

6-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N(R¹³), O, S and S(O)₂, and which may be substituted on ring carbon atoms with up to three substituents independently selected from the group consisting of fluoro, (C₁-C₄)-alkyl, oxo, hydroxy, amino and aminocarbonyl, and wherein

R¹³ is hydrogen, (C₁-C₄)-alkyl, cyclopropyl, cyclobutyl, formyl or (C₁-C₄)-alkylcarbonyl,

and

R¹⁵ is methyl or ethyl,

with the proviso that G¹ is not chloro when G² is chloro or cyano, or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

3. The compound of formula (I) according to Claim 1 or 2, wherein

R¹ is methyl,

R² is methoxy,

G¹ represents methyl, oxazol-5-yl or the group -CH₂-OR³ or -CH₂-NR⁴R⁵, wherein

R³ is hydrogen, (C₁-C₄)-alkyl, cyclopropyl or cyclobutyl,

wherein said (C₁-C₄)-alkyl is optionally substituted with hydroxy, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl, ethoxycarbonyl, amino, aminocarbonyl, cyclopropyl, cyclobutyl or up to three fluoro atoms,

R⁴ is hydrogen, methyl or ethyl,

R⁵ is hydrogen, (C₁-C₄)-alkyl, acetyl, cyclopropyl, cyclobutyl or 2-oxopyrrolidin-3-yl,

wherein said (C₁-C₄)-alkyl is optionally substituted with hydroxy, hydroxycarbonyl, cyclopropyl or cyclobutyl,

or

R⁴ and R⁵ are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 5- or 6-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from NH and O, and which may be substituted on a ring carbon atom with oxo or hydroxy,

5 and

G² represents methyl or the group -CR^{8A}R^{8B}-OH, -CH₂-NR⁹R¹⁰ or -C(=O)-NR¹¹R¹², wherein

R^{8A} and R^{8B} are independently hydrogen or methyl,

R⁹ is hydrogen,

10 R¹⁰ is hydrogen, (C₁-C₄)-alkyl, acetyl, cyclopropyl, cyclobutyl or 2-oxopyrrolidin-3-yl,

wherein said (C₁-C₄)-alkyl is optionally substituted with hydroxy or aminocarbonyl,

R¹¹ is hydrogen or methyl,

15 R¹² is hydrogen, (C₁-C₄)-alkyl, cyclopropyl, cyclobutyl or 2-oxopyrrolidin-3-yl, wherein said (C₁-C₄)-alkyl is optionally substituted with hydroxy,

or

20 R⁹ and R¹⁰, or R¹¹ and R¹², respectively, are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 6-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N(R¹³), O and S(O)₂, and which may be substituted on ring carbon atoms with up to three substituents independently selected from the group consisting of fluoro, methyl, oxo, hydroxy, amino and aminocarbonyl, and wherein

25 R¹³ is hydrogen, formyl or acetyl,

or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

4. The compound of formula (I) according to Claim 1, 2 or 3, wherein

R¹ is methyl,

R² is methoxy,

G¹ represents the group -CH₂-OR³, wherein

R³ is (C₁-C₄)-alkyl optionally substituted with hydroxy, amino or aminocarbo-
nyl,

and

G² represents the group -CH₂-NR⁹R¹⁰ or -C(=O)-NR¹¹R¹², wherein

R⁹ is hydrogen,

R¹⁰ is 2-oxopyrrolidin-3-yl,

or

R⁹ and R¹⁰ are joined and, taken together with the nitrogen atom to which they are
attached, form a piperazin-1-yl, 3-oxopiperazin-1-yl or 4-acetylpiperazin-
1-yl ring,

R¹¹ is hydrogen,

R¹² is 2-oxopyrrolidin-3-yl,

or


R¹¹ and R¹² are joined and, taken together with the nitrogen atom to which they are
attached, form a 3-hydroxyazetidin-1-yl, 4-hydroxypiperidin-1-yl or 3-oxo-
piperazin-1-yl ring,

or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

5. Process for preparing a compound of formula (I) as defined in Claims 1 to 4, characterized
in that


[A] a 6-substituted 4-aminopyrrolo[2,1-f][1,2,4]triazine of formula (II)

- 236 -




wherein R^3 has the meaning indicated in Claim 1 to 4,

is at first reacted with formaldehyde and an amine of formula (III)




5 wherein R^9 and R^{10} have the meanings indicated in Claim 1 to 4,

in the presence of an acid to give a compound of formula (IV)



wherein R^3 , R^9 and R^{10} have the meanings indicated in Claim 1 to 4,

then brominated to a compound of formula (V)




10

wherein R^3 , R^9 and R^{10} have the meanings indicated in Claim 1 to 4,

and subsequently coupled with a benzothiophen-2-yl boronate of formula (VI)

- 237 -




wherein R^1 and R^2 have the meanings indicated in Claim 1 to 4,

and

R^{14} represents hydrogen or (C_1-C_4) -alkyl, or both R^{14} residues are linked together to form a $-(CH_2)_2-$, $-C(CH_3)_2-C(CH_3)_2-$, $-(CH_2)_3-$, $-CH_2-C(CH_3)_2-CH_2-$ or $-C(=O)-CH_2-N(CH_3)-CH_2-C(=O)-$ bridge,


in the presence of a palladium catalyst and a base to yield the target compound of formula (I-A)



wherein R^1 , R^2 , R^3 , R^9 and R^{10} have the meanings indicated in Claim 1 to 4,


or

[B] a 6-substituted 4-aminopyrrolo[2,1-f][1,2,4]triazine of formula (II)




wherein R^3 has the meaning indicated in Claim 1 to 4,

is at first formylated with *N,N*-dimethylformamide in the presence of phosphoryl chloride to an aldehyde of formula (VII)




5 wherein R^3 has the meaning indicated in Claim 1 to 4,
then brominated to a compound of formula (VIII)



wherein R^3 has the meaning indicated in Claim 1 to 4,


and subsequently coupled with a benzothiophen-2-yl boronate of formula (VI)



10 wherein R^1 , R^2 and R^{14} have the meanings indicated above,

in the presence of a palladium catalyst and a base to give a compound of formula (IX)


- 239 -



wherein R^1 , R^2 and R^3 have the meanings indicated in Claim 1 to 4,


which then is either

[B-1] reacted with an amine of formula (III)



wherein R^9 and R^{10} have the meanings indicated in Claim 1 to 4,


in the presence of an acid and a reducing agent to yield the target compound of formula (I-A)




wherein R^1 , R^2 , R^3 , R^9 and R^{10} have the meanings indicated in Claim 1 to 4,

or


[B-2] oxidized to a carboxylic acid of formula (X)

wherein R^1 , R^2 and R^3 have the meanings indicated in Claim 1 to 4,

and finally coupled with an amine of formula (XI)

wherein R^{11} and R^{12} have the meanings indicated in Claim 1 to 4,


in the presence of a condensing agent to yield the target compound of formula (I-B)




wherein R^1 , R^2 , R^3 , R^{11} and R^{12} have the meanings indicated in Claim 1 to 4,

or

[C] a 6-substituted 4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazine of formula (XII)




5 is at first coupled with a benzothiophen-2-yl boronate of formula (VI)




wherein R^1 , R^2 and R^{14} have the meanings indicated above,

in the presence of a palladium catalyst and a base to give a compound of formula (XIII)




10 wherein R^1 and R^2 have the meanings indicated in Claim 1 to 4,

and then reacted with formaldehyde and an amine of formula (III)



wherein R^9 and R^{10} have the meanings indicated in Claim 1 to 4,


in the presence of an acid to yield the compound of formula (I-C)



wherein R¹, R², R⁹ and R¹⁰ have the meanings indicated in Claim 1 to 4,


which subsequently is either

5 [C-1] oxidized to an aldehyde of formula (XIV)



wherein R¹, R², R⁹ and R¹⁰ have the meanings indicated in Claim 1 to 4,


and treated with an amine of formula (XV)



10

wherein R⁴ and R⁵ have the meanings indicated in Claim 1 to 4,

in the presence of an acid and a reducing agent to yield the target compound of formula (I-D)




wherein R¹, R², R⁴, R⁵, R⁹ and R¹⁰ have the meanings indicated in Claim 1 to 4,

5

or

[C-2] converted into the corresponding 6-(halomethyl) derivative of formula (XVI)




wherein R¹, R², R⁹ and R¹⁰ have the meanings indicated in Claim 1 to 4,

and

10


X is chloro, bromo or iodo,

and treated with an alcohol of formula (XVII)



wherein R^{3A} has the meaning of R^3 as indicated in Claim 1 to 4, except for hydrogen,

in the presence of a base to yield the target compound of formula (I-E)



wherein R^1 , R^2 , R^{3A} , R^9 and R^{10} have the meanings indicated above,


optionally followed, where appropriate, by (i) separating the compounds of formula (I) thus obtained into their respective enantiomers and/or diastereomers, and/or (ii) converting the compounds of formula (I) into their respective hydrates, solvates, salts and/or hydrates or solvates of the salts by treatment with the corresponding solvents and/or acids or bases.

6. Compound as defined in any of Claims 1 to 4 for the treatment and/or prevention of diseases.
7. Compound as defined in any of Claims 1 to 4 for use in a method for the treatment and/or prevention of cancer and tumor diseases.
8. Use of a compound as defined in any of Claims 1 to 4 for the manufacture of a pharmaceutical composition for the treatment and/or prevention of cancer and tumor diseases.
9. Pharmaceutical composition comprising a compound as defined in any of Claims 1 to 4 and one or more pharmaceutically acceptable excipients.
10. The pharmaceutical composition of Claim 9 further comprising one or more additional therapeutic agents.

11. The pharmaceutical composition as defined in Claim 9 or 10 for the treatment and/or prevention of cancer and tumor diseases.
 12. Method for the treatment and/or prevention of cancer and tumor diseases in a mammal, comprising administering to a mammal in need thereof a therapeutically effective amount of one or more compounds as defined in any of Claims 1 to 4, or of a pharmaceutical composition as defined in any of Claims 9 to 11.
- 5

CLAIMS

1. A compound of formula (I)



wherein

R¹ is hydrogen, chloro, methyl or methoxy,

R² is hydrogen or methoxy,

with the proviso that at least one of R¹ and R² is other than hydrogen,

G¹ represents chloro, (C₁-C₄)-alkyl, (C₁-C₄)-alkoxycarbonyl, 5-membered aza-heteroaryl, or the group -CH₂-OR³, -CH₂-NR⁴R⁵ or -C(=O)-NR⁴R⁶, wherein

R³ is hydrogen, (C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl or phenyl,

(i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, (C₁-C₄)-alkoxy, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl, amino, aminocarbonyl, mono-(C₁-C₄)-alkylaminocarbonyl, di-(C₁-C₄)-alkylaminocarbonyl, (C₃-C₆)-cycloalkyl or up to three fluoro atoms,

and

(ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

and

(iii) said phenyl is optionally substituted with one or two substituents independently selected from the group consisting of fluoro, chloro, bromo,

cyano, trifluoromethyl, trifluoromethoxy, (C₁-C₄)-alkyl and (C₁-C₄)-alkoxy,

R⁴ is hydrogen or (C₁-C₄)-alkyl,

R⁵ is hydrogen, (C₁-C₄)-alkyl, (C₁-C₄)-alkylcarbonyl, (C₃-C₆)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein

(i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, (C₁-C₄)-alkoxy, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl, aminocarbonyl, mono-(C₁-C₄)-alkylaminocarbonyl, di-(C₁-C₄)-alkylaminocarbonyl or (C₃-C₆)-cycloalkyl,

and

(ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

and

(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy, oxo and amino,

R⁶ is hydrogen, (C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein

(i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, (C₁-C₄)-alkoxy, hydroxycarbonyl, (C₁-C₄)-alkoxycarbonyl, amino, aminocarbonyl, mono-(C₁-C₄)-alkylaminocarbonyl, di-(C₁-C₄)-alkylaminocarbonyl or (C₃-C₆)-cycloalkyl,

and

(ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

and

(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy, oxo and amino,

or

R⁴ and R⁵, or R⁴ and R⁶, respectively, are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 7-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N(R⁷) and O, and which may be substituted on ring carbon atoms with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, oxo, hydroxy, amino and aminocarbonyl, and wherein

R⁷ is hydrogen, (C₁-C₄)-alkyl, formyl or (C₁-C₄)-alkylcarbonyl,

and

G² represents chloro, cyano, (C₁-C₄)-alkyl, or the group -CR^{8A}R^{8B}-OH, -CH₂-NR⁹R¹⁰, -C(=O)-NR¹¹R¹² or -CH₂-OR¹⁵, wherein

R^{8A} and R^{8B} are independently selected from the group consisting of hydrogen, (C₁-C₄)-alkyl, cyclopropyl and cyclobutyl,

R⁹ is hydrogen or (C₁-C₄)-alkyl,

R¹⁰ is hydrogen, (C₁-C₄)-alkyl, (C₁-C₄)-alkylcarbonyl, (C₃-C₆)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein

(i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, amino, aminocarbonyl, mono-(C₁-C₄)-alkylaminocarbonyl or di-(C₁-C₄)-alkylaminocarbonyl,

and

(ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

and

(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy, oxo and amino,

R¹¹ is hydrogen or (C₁-C₄)-alkyl,

R¹² is hydrogen, (C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl or 4- to 6-membered heterocycloalkyl, wherein

(i) said (C₁-C₄)-alkyl is optionally substituted with hydroxy, amino, aminocarbonyl, mono-(C₁-C₄)-alkylaminocarbonyl or di-(C₁-C₄)-alkylaminocarbonyl,

and

(ii) said (C₃-C₆)-cycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy and amino,

and

(iii) said 4- to 6-membered heterocycloalkyl is optionally substituted with one or two substituents independently selected from the group consisting of (C₁-C₄)-alkyl, hydroxy, oxo and amino,

or

R⁹ and R¹⁰, or R¹¹ and R¹², respectively, are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 7-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N(R¹³), O, S and S(O)₂, and which may be substituted on ring carbon atoms with up to three substituents independently selected from the group consisting of fluoro, (C₁-C₄)-alkyl, oxo, hydroxy, amino and aminocarbonyl, and wherein

R¹³ is hydrogen, (C₁-C₄)-alkyl, (C₃-C₆)-cycloalkyl, formyl or (C₁-C₄)-alkylcarbonyl,

and

R¹⁵ is (C₁-C₄)-alkyl,

with the proviso that G^1 is not chloro when G^2 is chloro or cyano,

or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

2. The compound of formula (I) according to Claim 1, wherein

R^1 is chloro, methyl or methoxy,

R^2 is hydrogen or methoxy,

G^1 represents chloro, (C_1-C_4) -alkyl, (C_1-C_4) -alkoxycarbonyl or 5-membered aza-hetero-aryl selected from the group consisting of pyrazolyl, imidazolyl, oxazolyl, isoxazolyl and oxadiazolyl, or represents the group $-CH_2-OR^3$ or $-CH_2-NR^4R^5$, wherein

R^3 is hydrogen, (C_1-C_4) -alkyl or (C_3-C_6) -cycloalkyl,

wherein said (C_1-C_4) -alkyl is optionally substituted with hydroxy, (C_1-C_4) -alkoxy, hydroxycarbonyl, (C_1-C_4) -alkoxycarbonyl, amino, aminocarbonyl, (C_3-C_6) -cycloalkyl or up to three fluoro atoms,

R^4 is hydrogen or (C_1-C_4) -alkyl,

R^5 is hydrogen, (C_1-C_4) -alkyl, (C_1-C_4) -alkylcarbonyl, (C_3-C_6) -cycloalkyl or 5- or 6-membered heterocycloalkyl, wherein

(i) said (C_1-C_4) -alkyl is optionally substituted with hydroxy, hydroxycarbonyl or (C_3-C_6) -cycloalkyl,

and

(ii) said 5- or 6-membered heterocycloalkyl is optionally substituted with oxo,

or

R^4 and R^5 are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 6-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from $N(R^7)$ and O, and which may be substituted on a ring carbon atom with oxo or hydroxy, and wherein

R^7 is hydrogen or (C_1-C_4) -alkyl,

and

G^2 represents chloro, cyano, (C_1-C_4) -alkyl, or the group $-CR^{8A}R^{8B}-OH$, $-CH_2-NR^9R^{10}$, $-C(=O)-NR^{11}R^{12}$ or $-CH_2-OR^{15}$, wherein

R^{8A} and R^{8B} are independently selected from the group consisting of hydrogen, (C_1-C_4) -alkyl and cyclopropyl,

R^9 is hydrogen or methyl,

R^{10} is hydrogen, (C_1-C_4) -alkyl, (C_1-C_4) -alkylcarbonyl, (C_3-C_6) -cycloalkyl or 5- or 6-membered heterocycloalkyl, wherein

(i) said (C_1-C_4) -alkyl is optionally substituted with hydroxy or aminocarbonyl,

and

(ii) said 5- or 6-membered heterocycloalkyl is optionally substituted with oxo,

R^{11} is hydrogen or methyl,

R^{12} is hydrogen, (C_1-C_4) -alkyl, (C_3-C_6) -cycloalkyl or 5- or 6-membered heterocycloalkyl, wherein

(i) said (C_1-C_4) -alkyl is optionally substituted with hydroxy,

and

(ii) said 5- or 6-membered heterocycloalkyl is optionally substituted with oxo,

or

R^9 and R^{10} , or R^{11} and R^{12} , respectively, are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 6-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from $N(R^{13})$, O, S and $S(O)_2$, and which may be substituted on ring carbon atoms with up to three substituents independently selected from the group consisting of fluoro, (C_1-C_4) -alkyl, oxo, hydroxy, amino and aminocarbonyl, and wherein

R^{13} is hydrogen, (C₁-C₄)-alkyl, cyclopropyl, cyclobutyl, formyl or (C₁-C₄)-alkylcarbonyl,

and

R^{15} is methyl or ethyl,

with the proviso that G^1 is not chloro when G^2 is chloro or cyano,

or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

3. The compound of formula (I) according to Claim 1 or 2, wherein

R^1 is methyl,

R^2 is methoxy,

G^1 represents methyl, oxazol-5-yl or the group $-CH_2-OR^3$ or $-CH_2-NR^4R^5$, wherein

R^3 is hydrogen, (C₁-C₄)-alkyl, cyclopropyl or cyclobutyl,

wherein said (C₁-C₄)-alkyl is optionally substituted with hydroxy, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl, ethoxycarbonyl, amino, aminocarbonyl, cyclopropyl, cyclobutyl or up to three fluoro atoms,

R^4 is hydrogen, methyl or ethyl,

R^5 is hydrogen, (C₁-C₄)-alkyl, acetyl, cyclopropyl, cyclobutyl or 2-oxopyrrolidin-3-yl,

wherein said (C₁-C₄)-alkyl is optionally substituted with hydroxy, hydroxycarbonyl, cyclopropyl or cyclobutyl,

or

R^4 and R^5 are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 5- or 6-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from NH and O, and which may be substituted on a ring carbon atom with oxo or hydroxy,

and

G^2 represents methyl or the group $-CR^{8A}R^{8B}-OH$, $-CH_2-NR^9R^{10}$ or $-C(=O)-NR^{11}R^{12}$, wherein

R^{8A} and R^{8B} are independently hydrogen or methyl,

R⁹ is hydrogen,

R¹⁰ is hydrogen, (C₁-C₄)-alkyl, acetyl, cyclopropyl, cyclobutyl or 2-oxopyrrolidin-3-yl,

wherein said (C₁-C₄)-alkyl is optionally substituted with hydroxy or amino-carbonyl,

R¹¹ is hydrogen or methyl,

R¹² is hydrogen, (C₁-C₄)-alkyl, cyclopropyl, cyclobutyl or 2-oxopyrrolidin-3-yl,

wherein said (C₁-C₄)-alkyl is optionally substituted with hydroxy,

or

R⁹ and R¹⁰, or R¹¹ and R¹², respectively, are joined and, taken together with the nitrogen atom to which they are attached, form a monocyclic, saturated 4- to 6-membered heterocycloalkyl ring which may contain a second ring heteroatom selected from N(R¹³), O and S(O)₂, and which may be substituted on ring carbon atoms with up to three substituents independently selected from the group consisting of fluoro, methyl, oxo, hydroxy, amino and amino-carbonyl, and wherein

R¹³ is hydrogen, formyl or acetyl,

or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

4. The compound of formula (I) according to Claim 1, 2 or 3, wherein

R¹ is methyl,

R² is methoxy,

G¹ represents the group -CH₂-OR³, wherein

R³ is (C₁-C₄)-alkyl optionally substituted with hydroxy, amino or aminocarbonyl,

and

G² represents the group -CH₂-NR⁹R¹⁰ or -C(=O)-NR¹¹R¹², wherein

R⁹ is hydrogen,

R¹⁰ is 2-oxopyrrolidin-3-yl,

or

R⁹ and R¹⁰ are joined and, taken together with the nitrogen atom to which they are attached, form a piperazin-1-yl, 3-oxopiperazin-1-yl or 4-acetylpiperazin-1-yl ring,

R¹¹ is hydrogen,


R¹² is 2-oxopyrrolidin-3-yl,

or

R¹¹ and R¹² are joined and, taken together with the nitrogen atom to which they are attached, form a 3-hydroxyazetidin-1-yl, 4-hydroxypiperidin-1-yl or 3-oxopiperazin-1-yl ring,


or a pharmaceutically acceptable salt, hydrate and/or solvate thereof.

5. The compound 4-{{[4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1 f]-[1,2,4]-triazin-7-yl]methyl}piperazin-2-one according to claim 1 to 4,




or a pharmaceutically acceptable salt, hydrate, or solvate thereof.

6. The compound 4-{[4-Amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]-triazin-7-yl]methyl}piperazin-2-one according to claim 1 to 4,




7. Process for preparing a compound of formula (I) as defined in Claims 1 to 6, characterized in that

[A] a 6-substituted 4-aminopyrrolo[2,1-f][1,2,4]triazine of formula (II)




wherein R³ has the meaning indicated in Claim 1 to 4,

is at first reacted with formaldehyde and an amine of formula (III)




wherein R⁹ and R¹⁰ have the meanings indicated in Claim 1 to 4,

in the presence of an acid to give a compound of formula (IV)




wherein R^3 , R^9 and R^{10} have the meanings indicated in Claim 1 to 4,

then brominated to a compound of formula (V)



wherein R^3 , R^9 and R^{10} have the meanings indicated in Claim 1 to 4,

and subsequently coupled with a benzothiophen-2-yl boronate of formula (VI)




wherein R^1 and R^2 have the meanings indicated in Claim 1 to 4,

and

R^{14} represents hydrogen or (C_1-C_4) -alkyl, or both R^{14} residues are linked together to form a $-(CH_2)_2-$, $-C(CH_3)_2-C(CH_3)_2-$, $-(CH_2)_3-$, $-CH_2-C(CH_3)_2-CH_2-$ or $-C(=O)-CH_2-N(CH_3)-CH_2-C(=O)-$ bridge,


in the presence of a palladium catalyst and a base to yield the target compound of formula (I-A)



wherein R^1 , R^2 , R^3 , R^9 and R^{10} have the meanings indicated in Claim 1 to 4,


or

[B] a 6-substituted 4-aminopyrrolo[2,1-f][1,2,4]triazine of formula (II)




wherein R^3 has the meaning indicated in Claim 1 to 4,

is at first formylated with *N,N*-dimethylformamide in the presence of phosphoryl chloride to an aldehyde of formula (VII)




wherein R^3 has the meaning indicated in Claim 1 to 4,

then brominated to a compound of formula (VIII)




wherein R³ has the meaning indicated in Claim 1 to 4,

and subsequently coupled with a benzothiophen-2-yl boronate of formula (VI)



wherein R¹, R² and R¹⁴ have the meanings indicated above,


in the presence of a palladium catalyst and a base to give a compound of formula (IX)



wherein R¹, R² and R³ have the meanings indicated in Claim 1 to 4,


which then is either

[B-1] reacted with an amine of formula (III)



wherein R⁹ and R¹⁰ have the meanings indicated in Claim 1 to 4,


in the presence of an acid and a reducing agent to yield the target compound of formula (I-A)



wherein R¹, R², R³, R⁹ and R¹⁰ have the meanings indicated in Claim 1 to 4,


or

[B-2] oxidized to a carboxylic acid of formula (X)




wherein R¹, R² and R³ have the meanings indicated in Claim 1 to 4,

and finally coupled with an amine of formula (XI)



wherein R¹¹ and R¹² have the meanings indicated in Claim 1 to 4,


in the presence of a condensing agent to yield the target compound of formula (I-B)




wherein R¹, R², R³, R¹¹ and R¹² have the meanings indicated in Claim 1 to 4,

or

[C] a 6-substituted 4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazine of formula (XII)




is at first coupled with a benzothiophen-2-yl boronate of formula (VI)




wherein R¹, R² and R¹⁴ have the meanings indicated above,

in the presence of a palladium catalyst and a base to give a compound of formula (XIII)




wherein R^1 and R^2 have the meanings indicated in Claim 1 to 4,

and then reacted with formaldehyde and an amine of formula (III)



wherein R^9 and R^{10} have the meanings indicated in Claim 1 to 4,


in the presence of an acid to yield the compound of formula (I-C)



wherein R^1 , R^2 , R^9 and R^{10} have the meanings indicated in Claim 1 to 4,


which subsequently is either

[C-1] oxidized to an aldehyde of formula (XIV)




wherein R^1 , R^2 , R^9 and R^{10} have the meanings indicated in Claim 1 to 4,

and treated with an amine of formula (XV)



wherein R^4 and R^5 have the meanings indicated in Claim 1 to 4,


in the presence of an acid and a reducing agent to yield the target compound of formula (I-D)



wherein R^1 , R^2 , R^4 , R^5 , R^9 and R^{10} have the meanings indicated in Claim 1 to 4,

or

[C-2] converted into the corresponding 6-(halomethyl) derivative of formula (XVI)




wherein R^1 , R^2 , R^9 and R^{10} have the meanings indicated in Claim 1 to 4,

and


X is chloro, bromo or iodo,

and treated with an alcohol of formula (XVII)



wherein R^{3A} has the meaning of R^3 as indicated in Claim 1 to 4, except for hydrogen,

in the presence of a base to yield the target compound of formula (I-E)



wherein R^1 , R^2 , R^{3A} , R^9 and R^{10} have the meanings indicated above,

optionally followed, where appropriate, by (i) separating the compounds of formula (I) thus obtained into their respective enantiomers and/or diastereomers, and/or (ii) converting the compounds of formula (I) into their respective hydrates, solvates, salts and/or hydrates or solvates of the salts by treatment with the corresponding solvents and/or acids or bases.

8. Compound as defined in any of Claims 1 to 6 for the treatment and/or prevention of diseases.
9. Compound as defined in any of Claims 1 to 6 for use in a method for the treatment and/or prevention of cancer and tumor diseases.
10. Use of a compound as defined in any of Claims 1 to 6 for the manufacture of a pharmaceutical composition for the treatment and/or prevention of cancer and tumor diseases.
11. Pharmaceutical composition comprising a compound as defined in any of Claims 1 to 6 and one or more pharmaceutically acceptable excipients.
12. The pharmaceutical composition of Claim 11 further comprising one or more additional therapeutic agents.
13. The pharmaceutical composition as defined in Claim 11 or 12 for the treatment and/or prevention of cancer and tumor diseases.